Agreement of treatment effects from observational studies and randomized controlled trials evaluating hydroxychloroquine, lopinavir-ritonavir, or dexamethasone for covid-19: meta-epidemiological study코로나19에 대한 히드록시클로로퀸, 로피나비르-리토나비르 또는 덱사메타손을 평가하는 관찰 연구 및 무작위 대조 시험의 치료 효과 일치: 메타 역학 연구Article Published on 2022-05-102022-09-11 Journal: The BMJ [Category] meta-analysis, 임상, [키워드] age agreement Analysis calculated Clinical data collected Comparisons complement conducted controlled trials COVID-19 treatment criteria data extraction database demographical and clinical data demographics Dexamethasone disease severity distribution Efficacy Epidemiological study evaluated Evidence Hydroxychloroquine identify independent Lopinavir Lopinavir-ritonavir Matched means Medicine meta-analysed meta-analyses Meta-analysis Network meta-analysis nine not significant observational studies observational study outcome outcomes overlapping Placebo PLOS proportion Randomized controlled trial RCT RCTs reported Ritonavir Safety sequential analysis Seven Sex significantly synthesis systematic review therapeutic intervention therapeutic interventions Treatment treatment effect treatment effects trial sequential analysis [DOI] 10.1136/bmj-2021-069400 PMC 바로가기 [Article Type] Article
Drugs used during the COVID-19 first wave in Vitoria-Gasteiz (Spain) and their presence in the environmentVitoria-Gasteiz(스페인)의 COVID-19 1차 물결 동안 사용된 약물과 환경에서의 존재Article Published on 2022-05-102022-09-11 Journal: The Science of the total environment [Category] COVID19(2023년), SARS, 치료기술, 치료제, [키워드] Administered affected Analysis Antiviral antiviral activity Azithromycin benefit cisatracurium city Concentration country COVID 19 COVID-19 COVID-19 pandemic defined detrimental effects dose drug Drug pollution first positive First wave healthcare professionals hospital Hydroxychloroquine ICUs intensive care unit intensive care units lAbel LC-q-Orbitrap Lopinavir LOPINAVIR AND RITONAVIR Lopinavir/ritonavir medium one health pandemic Patient patients pharmacoepidemiology positive potential risk proportion Quotient risk Ritonavir SARS-CoV2 selected drug selected drugs situation Spain target Target analysis. Treatment urgency Vitoria were used [DOI] 10.1016/j.scitotenv.2022.153122 PMC 바로가기 [Article Type] Article
Detoxifying SARS-CoV-2 antiviral drugs from model and real wastewaters by industrial waste-derived multiphase photocatalysts산업폐기물 유래 다상 광촉매로 모델 폐수 및 실제 폐수에서 SARS-CoV-2 항바이러스제 해독Article Published on 2022-05-052022-09-11 Journal: Journal of hazardous materials [Category] COVID19(2023년), SARS, 치료제, [키워드] Ammonium antiviral drug antiviral drugs applied Combination Concentration contrary COVID-19 pandemic Danio Degradation degrade Effect effective Efficiency Embryo highest hydrophilic Industrial Industrial waste Lopinavir LOPINAVIR AND RITONAVIR Multiphase photocatalyst Photocatalysis plant reported resulting Ritonavir SARS-CoV-2 temperature tested Toxicity treated Treatment visible light wastewater water Water pollution Water purification Water purification. X-ray diffraction zebrafish [DOI] 10.1016/j.jhazmat.2022.128300 PMC 바로가기 [Article Type] Article
Use of combined treatment of 3rd-generation cephalosporin, azithromycin and antiviral agents on moderate SARs-CoV-2 patients in South Korea: A retrospective cohort study한국에서 중등도 SARs-CoV-2 환자에 대한 3세대 세팔로스포린, 아지트로마이신 및 항바이러스제 병용 치료: 후향적 코호트 연구Article Published on 2022-05-042022-09-11 Journal: PLoS ONE [Category] COVID19(2023년), SARS, 치료제, [키워드] adjust administration adverse event Analysis analyzed Antibiotics antiviral agent Antiviral agents association Azithromycin baseline characteristics cephalosporin Clinical outcome Cohort cohorts Combined combined treatment conducted confounding factors COVID-19 COVID-19 patient Cox regression analysis Cox regression method death Efficacy and safety Endpoint endpoints Evidence groups hazard ratio hazard ratios Hospital stay Hydroxychloroquine inclusion criteria Kaplan-Meier Kaplan-Meier curve Kaplan-Meier curves laboratory-confirmed Lopinavir Lopinavir/ritonavir low-dose mild to moderate Mild to moderate COVID-19 moderate Moderate COVID-19 moderate COVID-19 patients no significant difference no significant differences not significant Patient performed Prevent Propensity score propensity score matching PSM retrospective cohort study Ritonavir SARS-CoV-2 SARS-CoV-2 patient SARS-CoV-2 patients significant differences South South Korea Standard standard supportive care statistical significance Supportive treatment symptom resolution Time to symptom resolution Treatment treatment arm treatment group viral clearance were used [DOI] 10.1371/journal.pone.0267645 PMC 바로가기 [Article Type] Article
Inhibitory potential of repurposed drugs against the SARS-CoV-2 main protease: a computational-aided approachArticle Published on 2022-05-012022-10-04 Journal: Journal of biomolecular structure & dynamics [Category] COVID19(2023년), SARS, 신약개발, [키워드] approach approaches binding binding score binding site carried co-crystallized complexes coronavirus disease COVID-19 demonstrated develop docking docking result docking study drug FIVE form higher affinity Hypothesis in silico increase in Infection inhibitors of SARS-CoV-2 inhibitory effect Interaction investigated lamivudine Ligand ligands Lopinavir M pro molecular docking molecular dynamics Mortality MPro physico-chemical properties Plerixafor predicted Protease inhibitor Protein receptor Repurposed drug residue RMSD fluctuation SARS-CoV-2 the SARS-CoV-2 trajectory treat [DOI] 10.1080/07391102.2020.1847197 PMC 바로가기 [Article Type] Article
Hospital compounding to face shortage: A case study of the development of a lopinavir-ritonavir oral suspension during the first wave of SARS-COV-2 in FranceArticle Published on 2022-05-012023-07-06 Journal: Annales pharmaceutiques françaises [Category] COVID19(2023년), [키워드] Control strategy Lopinavir Oral suspension Pénurie Pharmaceutical compounding Préparation hospitalière Ritonavir shortage Stratégie de contrôle Suspension orale. [DOI] 10.1016/j.pharma.2021.09.002 PMC 바로가기
COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?COVID-19와 소분자 치료제의 약속: 배워야 할 교훈이 있습니까?Review Published on 2022-05-012022-09-11 Journal: Pharmacological research [Category] COVID19(2023년), SARS, 변종, 신약개발, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 adjuvant therapy Antiviral antiviral agent Antiviral agents antivirals Baricitinib Baricitinib (PubChem CID: 44205240) Chloroquine Chloroquine (PubChem CID: 2719) coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 Critical developmental Dexamethasone Dexamethasone (PubChem CID: 5743) drug Drug discovery effective Endemic Healthcare professional healthcare professionals Hydroxychloroquine Hydroxychloroquine (PubChem CID: 3652) Inclusion Ivermectin Ivermectin (PubChem CID: 6321424) limitation Lopinavir Lopinavir (PubChem CID: 92727) molnupiravir Molnupiravir (Pubchem CID: 145996610) Nirmatrelvir Nirmatrelvir (PubChem CID: 155903259) pandemic provided PubChem Remdesivir Remdesivir (PubChem CID: 121304016) researcher Retrospective analysis Ritonavir Ritonavir (PubChem CID: 392622) SARS-CoV-2 severe acute respiratory syndrome Coronavirus small molecule Small molecule therapeutics. standstill tested the disease therapy Treatment treatment of COVID-19 while with COVID-19 [DOI] 10.1016/j.phrs.2022.106201 PMC 바로가기 [Article Type] Review
Combination of QSAR, molecular docking, molecular dynamic simulation and MM-PBSA: analogues of lopinavir and favipiravir as potential drug candidates against COVID-19QSAR, 분자 도킹, 분자 동적 시뮬레이션 및 MM-PBSA의 조합: COVID-19에 대한 잠재적 약물 후보로서 로피나비르 및 파비피라비르의 유사체Article Published on 2022-05-012022-09-11 Journal: Journal of biomolecular structure & dynamics [Category] COVID19(2023년), SARS, 치료제, [키워드] Absorption active site analogue Analysis anti-viral drug Anti-viral drugs binding affinity candidate Candidates Compound COVID-19 COVID-19 infection COVID-19 infections demonstrated disease distribution docked complex docking drug candidate druggability effective enzyme Enzymes Favipiravir feature form identify IMPROVE in vitro inhibit Interaction less Lopinavir M pro metabolism Modification molecular molecular docking molecular dynamic simulations molecular dynamics Molecular dynamics simulation novel drug physicochemical polyprotein polyproteins processing protease QSAR Quantitative RdRP Replication residue RNA RNA polymerase RNA-dependent RNA polymerase SARS-CoV-2 selected shown significantly small molecule Small molecules Spread stable complex Toxicity trajectory translated Treatment Viral RNA viral RNA-dependent RNA polymerase [DOI] 10.1080/07391102.2020.1850355 PMC 바로가기 [Article Type] Article
Trial of Early Antiviral Therapies during Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19: a summary of the protocol and analysis plan for a decentralized randomized controlled trialCOVID-19에 대한 비입원 외래 환자 창(TREAT NOW) 중 조기 항바이러스 요법의 시험: 분산형 무작위 대조 시험에 대한 프로토콜 및 분석 계획 요약Article Published on 2022-04-082022-09-11 Journal: Trials [Category] COVID19(2023년), SARS, 임상, 치료제, [키워드] adaptive analysis plan Antiviral approach assigned Asymptomatic blinded clinical trial collected coronavirus disease Coronavirus disease 2019 COVID-19 Data collection death dropped drug duration of symptoms effective Efficacy enrolled Enrollment evaluate Evidence heterogeneous outcome Hospitalization Hydroxychloroquine individual interactions Lopinavir Lopinavir/ritonavir majority Mild symptom mild symptoms novel occur outcome Outpatient outpatients participant Placebo placebo-controlled platform Population Pragmatic Prevent progression protocol Randomized randomized clinical trial Randomized controlled trial Randomly receive reduce remote Ritonavir severe disease study drug Study participants Symptom telephone therapy treat treated treatments for COVID-19 Trial window [DOI] 10.1186/s13063-022-06213-z PMC 바로가기 [Article Type] Article
Pharmacological treatment of COVID-19: an opinion paperCOVID-19의 약리학적 치료: 의견서Review Published on 2022-04-012022-09-11 Journal: Revista española de quimioterapia : publicación [Category] COVID19(2023년), SARS, 치료제, [키워드] adalimumab Anakinra approach AZD7442 Azithromycin Banlanivimab Baricitinib BRII-196 BRII-198 canakinumab Casirivimab Certolizumab Ciganilmab Colchicine college Committee convalescent convalescent plasma COVID-19 Critical Dexamethasone drug drugs effective Efficacy English Etanercept etesevimab Evusheld Favipiravir fluvoxamine Golimumab help Hydroxychloroquine Imdevinab immune response Immunotherapy indication infliximab itolizumab Ivermectin Lemilumab Lopinavir Lopinavir/ritonavir Medicines metformin molnupiravir offer Pandemia pandemic Paxlovid PF-07321332 physician precocity prevented Ravulizumab Remdesivir Ritonavir ruxolitinib sarilumab SARS-CoV-2 Scientific Committee Sotrovimab Spanish the vaccine therapeutic Tixagevimab Tocilizumab Tofacitinib Treatment Vaccine virus Vitamin Vitamin D [DOI] 10.37201/req/158.2021 PMC 바로가기 [Article Type] Review